Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
REDWOOD CITY, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third
Toggle Summary Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentation of body composition data from the Company’s Phase
Toggle Summary Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting
REDWOOD CITY, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that body composition data from the Company’s Phase III trial,
Toggle Summary Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
Updated Results Demonstrate Significant DCCR Exposure Response Relationship Interim Analysis of Open-Label Extension Data Demonstrate Continued Efficacy Improvements in Body Composition and Metabolic Measures   Support Efficacy of DCCR in Treatment of PWS   Symptoms REDWOOD CITY, Calif. , Sept.
Toggle Summary Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
REDWOOD CITY, Calif. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
REDWOOD CITY, Calif. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second
Toggle Summary Soleno Therapeutics Added to Russell 3000® Index
REDWOOD CITY, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has been added to the Russell 3000 ® Index at the
Toggle Summary Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif. , June 26, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics , Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of its previously announced
Toggle Summary Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
REDWOOD CITY, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics , Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public
Toggle Summary Soleno Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics , Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of